FDA reviews Sanofi's multiple myeloma drug isatuximab

The FDA has begun its review of Sanofi’s multiple myeloma drug isatuximab, as the French pharma prepares for a tussle with Johnson & Johnson’s blockbuster Darzalex.

Immediately after EU nod, England's NHS funds Sanofi skin ca...

Patients in England will be among those who are first to benefit from Sanofi and Regeneron’s new cancer immunotherapy Libtayo, after NICE recommended funding for a form of skin cancer immed

Almirall takes option on Dermira's eczema drug lebrikizumab

Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, in a bid to take on Sanofi/Regeneron's recently approved Dupixent.

Sanofi/Regeneron asthma trial casts doubt on IL-33 class pro...

Sanofi hands back neurology gene therapy rights to Voyager

Sanofi’s Genzyme unit has handed back rights to two neurology gene therapies to US biotech Voyager Therapeutics, as part of a rethink of the companies’ joint research.

Sanofi and Google join forces to create 'Innovation Lab'

Sanofi and Google are to create a virtual innovation lab, aiming to transform how future medicines and health services are delivered, using the power of data technology.